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A B S T R A C T
In the quest for novel neurotechnologies to defeat brain diseases, intelligent biohybrid systems have earned a
privileged role among unconventional brain repair strategies. These systems are based on the functional
interaction between the nervous tissue and engineered devices, the establishment of which is mediated by
artiﬁcial intelligence. As novel, previously unimaginable neurotechnologies are emerging, what are the
translational impact and the practical consequences carried by these tools for the clinical practice?
In this review, we describe the progression of brain repair strategies, from the early pioneering
demonstration of their feasibility to their recent implementation in the experimental and clinical settings.
We will show how the convergence of diﬀerent disciplines across the decades has led to the emergence of
innovative concepts based on intelligent biohybrid designs. We discuss the advantages and limitations of the
described approaches and we conclude by proposing possible solutions to the current shortcomings of available
paradigms.
Focal points.
• Benchside
– Intelligent biohybrid systems represent the new era of cross-
disciplinary brain repair strategies, where biological and artiﬁcial
means complement each other.
– Establishment of the cross-disciplinary research approach as a
global vision will change the canonical concept of research team,
leading to the exponential progress of biomedical applicative
outcomes.
• Bedside
– Intelligent biohybrid systems will become the landmark of future
individualized therapeutic interventions for (self) repair of the
damaged brain.
– Aggressive pharmacological therapies will no longer be needed.
– Risky repetitive neurosurgical interventions may no longer be
needed: implantable biocompatible biohybrid systems act as
autonomous stand-alone therapeutic agents that will require less
frequent maintenance.
– The foreign body reaction may be minimized or even prevented
by the microﬂuidic-aided local delivery of immune-modulating
pharmacological agents, without need of systemic immunosup-
pressive treatment.
• Industry
– Industries belonging to the single specialty such as pharmaceu-
ticals, electronic medical devices and nanotechnologies as well as
stem cells & DNA banks will beneﬁt from each other by joining a
global industry for the development of implantable biohybrid
devices.
• Community
– The patients’ quality of life will signiﬁcantly improve while their
life expectation will be prolonged.
– The societal stigma associated with certain neurological condi-
tions will be defeated.
• Governments
– The inherent cross-disciplinary approach of Research &
Development in the ﬁeld of intelligent biohybrid neurotechnolo-
gies eliminates the requirement of planning time-consuming
investigation-production chains, since these tasks will be per-
formed simultaneously.
– The more eﬃcient use of funding along with the high impact of
implantable biohybrid devices on health-care and society will
attract funding from Governments to support the global engage-
ment of research teams and industries.
http://dx.doi.org/10.1016/j.nhtm.2016.10.001
Received 21 July 2016; Accepted 7 October 2016
⁎ Corresponding author.
E-mail address: gabriella.panuccio@iit.it (G. Panuccio).
Abbreviations: ANN, artiﬁcial neural network; BMI, brain-machine interface; CLDA, closed-loop decoder adaptation; CNS, central nervous system; CPG, central pattern generator;
DBS, deep-brain stimulation; iPSC, induced pluripotent stem cell; SNN, spiking neural network; TBI, traumatic brain injury; tES, transcranial electrical stimulation; TMS,
transcranial magnetic stimulation
New Horizons in Translational Medicine 3 (2016) 162–174
2307-5023/ © 2016 The Authors. Published by Elsevier Ltd on behalf of European Society for Translational Medicine. This is an open access article under the  CC BY-NC-ND license
(http://creativecommons.org/licenses/by/4.0/).
Available online 12 October 2016
– The establishment of biohybrid therapeutics as the gold standard
in the treatment of neurological disorders will signiﬁcantly reduce
the global burden of disease by cutting the costs of long-term care
and of chronic treatment.
• Regulatory agencies
– The advent of intelligent biohybrid neurotechnologies for brain
self-repair will simplify the procedure of therapeutics approval
thanks to (i) the possibility of leveraging self-grafting of patient-
derived neuronal elements, (ii) in vitro testing of the functional
features of intelligent biohybrid grafts prior to their transplanta-
tion to the patient's brain and (iii) simpliﬁed procedures for
parameter optimization.
1. Introduction
One billion people worldwide suﬀer for disorders of the central
nervous system (CNS). The greatest burden is carried by neurodegen-
erative diseases, epilepsy and stroke [1]. These patients (and their
caregivers) face daily challenges in their lives due to cognitive and
physical impairment. Moreover, the side eﬀects inherent to the use of
available medications or to routine neurosurgery interventions further
impact on the patient's quality of life with signiﬁcant consequences on
public health-care and society.
Research on brain repair strategies has progressed exponentially
over the last few decades. Several studies in the ﬁelds of regenerative
medicine, from one side, and neural engineering, from the other side,
are tackling the ‘brain repair issue’ by means of diﬀerent, complemen-
tary approaches. The biological approaches rely on the activation of the
endogenous regenerative capacity of the brain and on cell transplanta-
tion, while the engineering strategies include neuromodulation, repla-
cing and bridging techniques and brain-machine interfaces (BMIs)
(Fig. 1).
However, none of these strategies has actually proved suﬃcient to
deﬁnitely heal functionally and/or anatomically a damaged brain due
to the drawbacks inherent to their sole exploitation.
In light of these issues, the vision that biological and engineering
means should complement each other through a functional partnership
has started getting oﬀ the ground, which is why tools from artiﬁcial
intelligence have come into play. Thus, intelligent biohybrid systems
are starting to gain the general consensus of the brain repair scientiﬁc
community, as they challenge the limitations of conventional ap-
proaches. As recently reappraised [2], a system of biohybrid architec-
ture is constituted whenever an artiﬁcial device is coupled to the brain
and interferes with or is activated by its activity. Intelligent biohybrid
systems additionally implement artiﬁcial intelligence, which is lever-
aged to aid in the seamless integration of biological and engineering
components.
In this review we describe the concepts at the core of intelligent
biohybrid systems at their current state of the art, relative to the
neurotechnology ﬁeld. To motivate the need of the intelligent biohybrid
design, we ﬁrst provide an overview of the current approaches explored
by biology and engineering disciplines, portraying their historical
development and describing the advantages and limitations of their
sole use both in the experimental and in the clinical settings. Particular
emphasis is given to the engineering approach in light of its predomi-
nance in biohybrid neurotechnologies. We then describe emerging
unconventional strategies exploiting an intelligent biohybrid design
and their applicative perspectives. We conclude by presenting some
fundamental open questions and indicating possible new directions in
approaching the functional and anatomical recovery of the damaged
brain.
2. The biological approach to brain repair: reconstruction of
the damaged brain tissue by endogenous neurogenesis or by
neuronal transplant
The exciting discoveries on adult neurogenesis over a century ago
[3–5] (reviewed by [6]), marked the inception of a new era in the
neurosciences by rejecting the canonical tenet that the brain cannot
repair itself. The prospective for brain self-repair is straightforward: by
employing targeted bio-cues, it might be possible to guide the migra-
tion of adult newly-generated neurons so to aid in the anatomical and
functional re-establishment of damaged brain areas. In 1962, the
groundbreaking discovery of Gurdon challenged the dogma that
specialization into a speciﬁc cell-type is an irreversible biological
process: he demonstrated that diﬀerentiated cells still contain the
machinery required to drive their development into any cell-type [7]. In
the wake of this pioneering demonstration, a new milestone has been
achieved in the next few decades, when induced pluripotent stem cells
(iPSCs) were ﬁrst generated from mice [8] and soon after from somatic
cells of adult humans by two independent laboratories [9,10], making
another landmark in the history of regenerative medicine and a
fundamental advancement in brain repair research. Indeed, iPSCs
may be diﬀerentiated into any cell-type, thus making it possible to
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Fig. 1. Biological and engineering approaches to functional brain repair. Schematic renditions of the currently available biological (left) and engineering (right) means exploited to
repair the dysfunctional brain tissue.
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‘patch’ damaged brain tissue with a great degree of ﬂexibility. Similarly,
grafting of embryonic neurons has been proposed as a promising
strategy to reestablish lost brain connections in the adulthood [11].
Techniques from tissue engineering have also put forward the trans-
plantation of neurospheroids (i.e., in vitro pre-made 3D neuronal
networks) with encouraging results [12]. More recently, the generation
of self-organized three-dimensional ‘mini-brains’ (so-called brain
organoids) from human iPSCs [13] has provided new means for
inducing the natural development of structured nervous tissue that
realistically reproduces the architecture of a real brain and validate its
functional features outside the patient's body. Such a discovery has
tremendous implications for functional brain repair, since it envisages
the possibility of generating ad hoc neuronal grafts straight from the
patient's iPSCs and modulate their structural and functional features
before their transfer into the patient's brain.
Each of these biological means has a great prospective potential but
is nonetheless inherently prone to fundamental drawbacks that limit
their clinical application. Most importantly the integration of exogen-
ous neuronal elements or the migration of endogenous neuronal stem
cells along with their proliferation, diﬀerentiation and survival within
the pathological environment needs to be carefully considered when
translating these techniques to the clinical setting [14,15]. Indeed,
while intrinsically endowed with plasticity and adaptation, biological
cells might evolve beyond control and in turn endanger the patient's
safety unless adequately ﬁne-tuned. The pathological environment
might predominate over the newly generated nervous tissue and
imprint pathological features to it, or the new cellular elements might
lead to the unexpected development of brain tumors. Moreover, the
inﬂammatory response triggered by brain damage generates a non-
permissive environment for endogenous regrowth and recovery of the
nervous tissue, as well as for the functional integration of grafted cells.
For example, it has been shown that the number of cellular elements
and the timing of their transplantation (the so-called ‘safe window’)
relative to the brain damage [16,17] are critical factors. In this
scenario, it should ideally be possible to halt the immune reaction of
the host environment while ﬁne-tuning the growth and the functional
features of the regenerative neuronal elements. As recently reviewed
[18–20], targeting both the extrinsic and intrinsic factors contributing
to the non-permissive axon-scar environment is a strategy worth to
explore. Indeed, it has been shown that the enzyme chondroitinase can
break down the tangled scar tissue which surrounds the brain lesion, so
to free neuronal processes from its restraining action and allow them to
grow again [21,22]. Moreover, antibody therapy has proved promising
in neutralizing the action of negative neuronal growth regulators, such
as Nogo [23–25]. Along with counteracting neuronal growth inhibition,
enhancement of the intrinsic growth potential of neurons via genetic or
pharmacological manipulation has produced encouraging axonal re-
generation [26,27]. These strategies have signiﬁcantly improved the
functional recovery in animal models of CNS injury. However, despite
these remarkable results, the available means strategically used to
improve the chance of successful brain regeneration or exogenous
repair have not yet defeated the main challenge of long-distance axon
regeneration, i.e., the recovery of functional and structural features to a
level that resembles the intact CNS. It follows that while the eﬀective-
ness of cell-based therapies is in the ﬁrst place undermined by the
adverse reactions of the hosting environment, the long-term functional
and anatomical outcomes of these approaches are unpredictable and
may ultimately lead to treatment failure. Table 1 summarizes the
advantages and limitations of the described biological approaches both
in the experimental and clinical settings.
Whereas control of the immune reaction and tissue growth is
intensively addressed by the study of pharmacological agents, biologi-
cal cues and gene therapy, imprinting of the desired functional
(electrophysiological) features to the regenerative nervous tissue is
still far from being a possible route. In fact, it would require the
coordinated modulation of the developing tissue patch and of the
damaged host brain so to avoid pathological electrical entraining of the
healthy graft while allowing it to exert its healing function. To achieve
this outstanding goal, tools from control engineering must come into
play and mediate the seamless integration of the graft into the host
nervous tissue under a controlled predictable environment.
3. The engineering approach to restore brain function:
control, replacement and bridging
The engineering approach to brain repair makes use of artiﬁcial
devices to restore the physiological brain function by (1) stimulating
the CNS (neuromodulation), (2) connecting the brain with an end
eﬀector (BMIs), (3) replacing/bypassing the damaged brain tissue
(neuroprosthetics).
In this section we describe the most basic engineering interventions
that represented a breakthrough in functional brain repair and we
discuss the technical limitations that have led to the development of
more sophisticated engineered devices based on advanced intelligent
algorithms. Being coupled to the brain tissue, these artiﬁcial devices
inherently give origin to a system of biohybrid architecture (see [2]).
Here, we use the terms engineering approach to describe the diﬀerent
designs of these engineered components and neuroprostheses to
indicate prosthetic devices having a direct connection with the CNS.
3.1. Neuromodulation
Neuromodulation refers to techniques of diﬀerent levels of inva-
siveness used to stimulate selected brain areas thereby modulating
their activity with therapeutic purposes in otherwise intractable
patients. Speciﬁcally, neuromodulation may be used to (1) interfere
with and rectify pathological brain activity and (2) favor functional
brain recovery (e.g. following injury) by aiding in plasticity phenomena.
The therapeutic eﬀects may be achieved via electrical or magnetic
stimulation delivered through the skull (transcranial electrical stimula-
tion (tES) and transcranial magnetic stimulation (TMS), respectively)
or via electrical pulses delivered directly into target deep brain areas
(deep brain stimulation, DBS). Here, we focus on DBS and tES systems
in light of their technical suitability and their current relevance to the
design of intelligent biohybrid systems for functional brain repair. Most
of the primary knowledge on the therapeutic eﬀects of these neuromo-
dulation techniques has been based on human research because of
lacking faithful animal models. However, the relatively recent avail-
ability of more reliable tools for preclinical testing have largely
contributed to the development of modern experimental paradigms
to further the investigation of these techniques in CNS disease models.
The therapeutic eﬀects of electricity on the human body have been
known since ancient times, when the electric ray was named Torpedo
nobiliana by the Romans and Narke by the Greeks after its ability of
inducing torpor and narcotizing those who had been shocked by the
contact with it. Scribonius Largus [28] used to employ the bioelec-
tricity generated by the Torpedo to treat chronic pain, headache and a
variety of other medical conditions [29,30]. The ﬁrst public demon-
stration that the brain cortex can be modulated by the application of
electrical pulses and in turn produce eﬀects on the human body was
provided in the early XIX century by Giovanni Aldini [31], whose
research was inspired by the seminal work of his uncle Luigi A. Galvani
[32,33]. In the next years, Aldini was able to successfully treat a patient
aﬀected by severe melancholia using transcranial galvanism (see [34]).
The ﬁrst ever direct electrical stimulation of the brain cortex of an
awake human was performed in 1874 by Robert Bartholow [35,36].
Electrical therapy has since then been intensively studied to treat a
wide spectrum of neurologic and psychiatric disorders (see [34,37–40]
for historical reviews).
The ﬁrst neuromodulation technique to be actually introduced in
the experimental clinical practice was tES at the beginning of the XX
century [41], thanks to the practical feasibility of the external
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approach. tES was used for induction of sleep and anesthesia [42], but
in the late 1960s it became clear these were rather side eﬀects of the
electrical stimulation, which opened the possibility of several thera-
peutic applications. Meanwhile, the advent of the ﬁrst stereotactic
apparatus for humans in the late 1940s [43] had made routine
employment of DBS feasible. Stereotactic DBS was ﬁrst applied in
the early 50s [44] to treat psychotic patients [45,46]. Its chronic
application was then proposed in the early 90s as a stand-alone
therapeutic strategy to control movement disorders [47,48].
While tES has been widely used in the past century as electro-
convulsive treatment of depression and psychosis, the Food & Drug
Administration (FDA) has recently reevaluated the eﬃcacy and safety
of this approach [49]. Nonetheless, the advantage of non-invasive
neuromodulation is in favor of further investigation on potential use.
Increasing evidence supports the adjuvant role of tES in post-stroke
rehabilitation to improve motor learning [50] and functional recovery
[51], possibly due to promotion of structural plasticity phenomena that
are crucial for recovery from a brain lesion [52]. However, a signiﬁcant
drawback of the transcranial approach is the low focality of the
delivered current, i.e., stimulation of highly selective targets is still
impractical [53]. Conversely, DBS is to date an established approach
that ﬁnds clinical application in a variety of movement disorders [54],
being oﬃcially approved by the FDA since 1997. Several clinical trials
have also shown promising therapeutic eﬀects against epileptic syn-
dromes [55,56], chronic pain [57], primary headache disorders [58]
and psychiatric syndromes [59,60], with constantly expanding inves-
tigations [61–65]. Although invasive, the greater popularity of DBS is
possibly due to the advantage of targeting in situ speciﬁc (even small
and deep) brain areas with the aid of stereotactic and imaging
guidance, while being relatively safe.
Besides the target brain area, relevant to brain repair are also (i)
the stimulation parameters and (ii) the algorithms that control the
stimulating device, whether DBS or tES is used.
As for the parameter choice, the CNS disease (and the neuronal
pathways involved) plays a major role, but intra-individual and inter-
individual variability along with the progression of the clinical condi-
tion and electrode/signal degradation in the case of DBS should also be
taken into account. Indeed, parameter ﬁne-tuning is ﬁrst done at the
time of electrode application whereas follow-up adjustments are
inherently required. Moreover, the functional improvement ceases
upon stimulation withdrawal. Needless to mention, the stress caused
to the brain tissue by a constantly-on DBS paradigm is not negligible.
Autonomic eﬀects [66] and modulation of neuronal pathways func-
tionally connected to the stimulated brain area [67] have also been
frequently described: although reversible, these eﬀects might represent
undesired outcomes of neuromodulation and should not be under-
estimated. Last but not least, similar to heart pace-makers, DBS devices
run on a battery, which needs to be replaced at some point in time,
essentially subjecting treated patients to ‘maintenance’ neurosurgery
(on average every 5 years).
With regard to the algorithms employed to control the stimulating
device, the systems currently used in the clinical setting mainly provide
a ﬁxed-frequency stimulation (also called periodic pacing). As their
function is not inﬂuenced by the ongoing brain activity, these devices
do not exhibit intelligent performance; rather they act as brain pace-
makers and are said to be unidirectional. The operation of these devices
is also regarded as open-loop, indicating that no feedback mechanism
is involved to forward the modulated brain activity back to the
modulator so to allow real-time adjustments of the control algorithm
(Fig. 2).
In practice, open-loop neuromodulation does not oﬀer the possibi-
lity of an individualized treatment, with the consequent shortcoming of
increased brain tissue stress (in the case of DBS) and shorter battery
life. Thus, despite the signiﬁcant relief of clinical symptoms, many
aspects should be considered in the reckoning of pros and contra of
open-loop paradigms.Ta
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Advanced neuromodulation techniques leverage the electrical brain
activity to trigger the stimulating apparatus. As the performance of
these devices depends on the feedback received from the brain, their
operation is regarded as closed-loop (Fig. 2). Some of these elements
are set to provide a single output, i.e., they enforce a reactive behavior
as in the case of electrical pulses delivered to a cortical area upon
detection of an electrical signal. Others are more ﬂexible in that they
are programmed to generate diﬀerent predeﬁned built-in options
according to diﬀerent brain inputs, enforcing a responsive behavior
(see [2]).
Using a reactive stimulation algorithm in brain-injured adult rats,
the group of Randolph J. Nudo demonstrated that the loss of motor
control could be successfully recovered by delivering electrical pulses to
select cortical areas with a predeﬁned delay following the detection of
an electrographic event in the somatosensory cortex [51]. This simple
but eﬀective phase-locked stimulation paradigm, deﬁned by the
authors as ‘activity-dependent stimulation’, was employed in the
context of a bridging approach (see below). Exploitation of a similar
design has also been reported to ameliorate Parkinsonism [68].
A responsive design was proposed by Beverlin and Netoﬀ [69]. By
using computer simulations, the authors were able to decrease the
seizing state of a simulated neural network by enforcing a frequency-
dependent stimulation policy. The algorithm was instructed to change
its stimulation frequency according to the neural ﬁring frequency,
based on built-in knowledge incorporated in the algorithm by the
experimenters. It is worth noting that the authors improperly deﬁne
this operating mode as ‘adaptive’, which implies intelligent behavior
(see [2]). However, this is not strictly the case here. Indeed, the
proposed design requires a knowledgeable external supervisor instruct-
ing the algorithm on how to proceed, i.e., it is based on supervised
learning, while the ultimate goal of the actions chosen by the algorithm
is not a required parameter.
Responsive neuromodulation has recently obtained the FDA ap-
proval for clinical application as adjunctive treatment for drug-
refractory epileptic syndromes [70]. The implantable device is pre-
programmed by a skilled neurosurgeon or physician who sets the
sequences of therapeutic interventions to be implemented upon
electrographic detection of a seizure [71,72]. The electrical stimulation
patterns are triggered one after the other in the exact sequence
established by the human operator so to maximize the eﬃcacy of the
intervention (seizure arrest). Despite being a valuable therapeutic tool
to ameliorate the clinical manifestations (and thus the quality of life) of
epileptic patients who do not respond well to the canonical pharma-
cological treatments, the responsive operation of this DBS system
inherently requires a time lag to recognize a seizing state. Thus,
responsive neuromodulation for epileptic disorders is not capable of
predicting and thus preventing an imminent seizure: it can only halt its
progression to the full-blown manifestation.
From what has been described so far, the beneﬁt of neuromodula-
tion is unquestionable. However, the control logic at the core of the
operation of these devices does not allow for a ﬂexible performance. As
already stressed, the output of available neuromodulators is still
passively bound to the ongoing brain activity in the most advanced
closed-loop designs. However, the patient would receive a greater
beneﬁt if a device were able to deliver an electrical pulse only when it is
most needed. To this aim, intelligent stimulation algorithms based on
real-time prediction of forthcoming electrical events and adaptation to
the ongoing brain electrical activity would be required. In the wider
context of biohybrid brain repair strategies, intelligent neuromodula-
tion would also serve the fundamental function of ﬁne-tuning the
functional features of the interacting graft and host nervous tissues.
3.2. Brain-machine interfaces
Brain-Machine interfaces (BMIs) are systems mediating the com-
munication between the brain and an external eﬀector. This branch of
the neurosciences was developed with the aim of restoring missing
motor functions in patients who had lost such abilities due to disabling
neurological diseases, CNS injury or limb amputation.
Almost 50 years ago Eberhard E. Fetz [73] demonstrated that
trained monkeys were able to voluntarily modulate the activity of their
cortical motor neurons in the absence of motion production. These
discoveries inspired the pioneering visions of Edward M. Schmidt [74],
who was able to demonstrate, ten years later, that monkeys could
modulate their cortical activity (recorded with chronically implanted
microwire arrays) so to move an eﬀector external to their bodies. In the
same period Apostolos P. Georgopoulos and colleagues [75] studied the
electrical activity of cortical motor neurons in the forelimb areas of
behaving monkeys and observed that each neuron was selectively
increasing its ﬁring rate when the primate was moving its forelimb in
a given direction. These observations lead to the conclusion that
speciﬁc movement trajectories activate speciﬁc ensembles of cortical
motor neurons and thus these ensembles are functionally linked to a
preferred direction. This unprecedented discovery helped
Georgepoulos and his colleagues predict the desired direction of the
primate's forelimb movement by computing the population vector, i.e.
the vector obtained by linearly combining the vectors speciﬁed by each
neuron's preferred direction, weighted by the neuron's instantaneous
ﬁring rate. All these studies laid the foundation for brain signal
decoding and the development of neuroprosthetics. However, twenty
years more of research had to elapse before BMIs were born.
The ﬁrst pioneering demonstration of the feasibility of this neu-
roengineering approach dates back to 1999, when Chapin and collea-
gues [76] showed that rats could move a robotic arm by modulating the
activity of their motor cortical neurons (Fig. 3).
These pioneering experiments suggested the possibility of creating
a new generation of neuroprosthetic devices based on the decoding of
brain signals in order to operate an end eﬀector. A decoding algorithm
(decoder) is a programmatic routine used to decode neuronal signals
into their functional meaning. The seminal work by Chapin and
colleagues represented its ﬁrst applicative demonstration, which was
followed by various decoder designs to interface brain and machines
making use of diﬀerent kinds of recording techniques. In 2006 the
group lead by John P. Donoghue [77] described the ﬁrst successful
prototype of BMI used in a human with tetraplegia. The BMI was able
to decode motor intentions from the hand motor area of the brain
cortex of the patient and translate it into the movement of a cursor on a
screen so to perform simple actions such as opening emails and
controlling television. The same group was later able to successfully
establish the functional connection of a robotic arm to the brain of a
patient with tetraplegia, allowing her to reach, grasp and drink a cup of
coﬀee [78]. A more advanced reactive BMI design has been recently
realized by Chad Bouton and colleagues [79]. With the aid of microwire
arrays chronically implanted in the motor cortex of a quadriplegic
young man, electrical signals corresponding to motor intentions were
decoded and translated into patterns of stimulation which were
forwarded to a custom neuromuscular electrical stimulation system
that consequently activated forearm muscles. The authors demon-
strated that this BMI design is able to translate intentions to motions
thereby restoring ﬁne hand-wrist movement in a paralyzed human by
providing for single ﬁnger control resulting in six diﬀerent hand
motions.
As seen, BMIs generally record brain signals from the hand or arm
areas of the motor cortex in order to decode motor intentions and use
this information to drive the end eﬀector. In a recent study, Alessandro
Vato and coworkers [80] built a BMI in rodents that was able to drive
the motion of a mass in a virtual ﬁeld by recording from the whiskers
motor area and consequently stimulating the naturally connected
whisker somatosensory area. They demonstrated that it was possible
to use two connected brain areas to implement a control policy over the
external end eﬀector, even if the controlled task (i.e. the motion of the
virtual mass) was not directly linked to the intrinsic physiological role
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of the brain regions used.
3.3. Brain prostheses for replacing or bypassing the damaged brain
tissue
Brain-prostheses can be deﬁned as a special kind of neuroprosth-
eses in which an artiﬁcial system, either software or hardware, is used
to bypass or replace a damaged brain area in order to regain the lost
functionality. Two are the main scientiﬁc and technological outcomes
which brought to the realization of these systems. In 1993 Sylvie
Renaud and colleagues [81] established the ﬁrst communication
channel between an artiﬁcial neuron and a biological neuronal net-
work. An evolution of that system was later published in Nature
by Gwendal Le Masson et al. [82], who reconstructed a hybrid
thalamocortical pathway by combining a biological network and an
artiﬁcial system constituted by a dedicated analog integrated circuit. In
this way the authors were able to work with a real biological system
while maintaining complete control over the parameters of the model
neuron. In 2000 Ferdinando A. Mussa-Ivaldi and coworkers [83]
created the ﬁrst hybrid neuro-robotic system: a two-way communica-
tion between the brain of a lamprey and a small mobile robot. These
studies allowed the establishment of a new concept of neuroprostheses
‘for the brain’ aimed at replacing the damaged neural tissue with a
structure incorporating an artiﬁcial component or on bridging two
brain areas to promote functional recovery following a brain damage.
The realization of such prostheses implies the knowledge of how to
interact with neuronal cell assemblies, taking into account the intrinsic
spontaneous activation of neuronal networks and understanding how
to drive them into a desired state in order to produce a speciﬁc
behavior. This outstanding long-term goal requires the development of
computational models to be fed with the recorded electrophysiological
patterns so to yield the appropriate brain stimulation pattern that
would recover the lost or compromised function(s). The models used in
this framework can be essentially of two types: (i) bio-inspired and (ii)
biomimetic. A bioinspired model is a system inspired by nature,
capturing an essential idea underpinning a biological system so to
implement its abstraction in technology, like the design of an aircraft
equipped with wings is inspired by a ﬂying bird. A biomimetic model
mimics the nature's modus operandi, trying to replicate features, like
early aircraft designs implementing ﬂapping of the wings. More
pertinent to biohybrid systems for brain repair is the typical example
of central pattern generators (CPGs), i.e., neuronal assemblies that
intrinsically generate rhythmic patterned outputs: a bio-inspired model
catches the essential feature of cyclic rhythm and would be a simple
oscillator, where frequency and duty cycle are kept constant, whereas a
biomimetic model further implements the features that a CPG exhibits
in the real world by introducing variable frequency and duty cycle in
the oscillator's design [84].
Replacing neuroprostheses – the ﬁrst example of brain prosthesis
for replacing a damaged brain circuit was proposed by the group of
Theodore Berger. They worked on the development of hippocampal
prostheses by using both in in vitro and in vivo experimental models
for memory enhancement. In one experiment [85] they employed a
non-linear software computational model to approximate the transfor-
fixed output
open-loop closed-loop
reactive output responsive output
’a a
b b’
NHTM Intelligent Biohybrid Systems
Fig. 2. Neuromodulation. Open loop devices deliver electrical pulses at a ﬁxed frequency regardless of the ongoing brain electrical activity. Closed-loop devices may be based on a
reactive policy (stimulation is phase-locked to brain patterns) or on a responsive policy, where the device's output changes according to built-in options. In this rendition brain pattern a
triggers output a′ while brain pattern b triggers output b′. Grey traces: ongoing brain electrical activity. Black traces: evoked brain electrical responses. Black vertical bars: time-stamps
of delivered electrical pulses.
Fig. 3. The ﬁrst BMI – experimental paradigm. In lever-movement/robot-arm mode (a)
rats were trained to obtain a water reward by pressing the lever (b), which was
electronically connected to a robot arm (c) used to collect water drops from the sipper
tube (e) hidden by a barrier (d). The rest position of the robot arm was by the rat, through
a slot in the barrier. An electronic controller was used to translate the lever displacement
and proportionally slide forward the robot arm through the slot in order to reach the
sipper tube and collect water drops. The robot arm carrying the water reward then
passively moved back to its rest position by the rat. In neuronal-population-function/
robot-arm mode (f), rats were chronically implanted with multi-electrode arrays (f) in
the M1 cortex and VL thalamus for simultaneous recordings of single-neuron electrical
activity (g) to extract spike trains (h) and neuronal-population (NP) function by principal
component analysis (i). A switch (j) was used to select the input source (lever movement
versus NP function) and consequently control the robot-arm position. In experiments,
rats typically began moving the lever. The input was then switched to the NP function,
yielding robot arm movements (and thus water reward) when the rat was to press the
lever (i.e., before the lever was actually displaced). The animal eventually learned to
obtain water through direct brain control of the robot arm (from Chapin et al. Real-time
control of a robot arm using simultaneously recorded neurons in the motor cortex.
Nature neuroscience 2 (7) (1999) 664–670 [76]).
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mation between the input and output spike trains of an observed
neuronal network. An iterative procedure was able to determine all the
parameters so that the model could predict the observed input-output
ﬁring patterns.
Neuromorphic devices (i.e., engineered systems that mimic the
complex parallel processing of the human brain) represent the latest
advancement in replacement neurotechnologies for brain repair. In
2015, Roni Hogri and coworkers [86] built a hardware biomimetic
circuit implementing cerebellar functions. The chip was interfaced in
real-time with cerebellar input and output nuclei of anaesthetized rats.
They demonstrated that functional rehabilitation can be achieved by
reproducing cerebellar-dependent learning. The team of the EU-funded
project Brain Bow presented the ﬁrst results related to the realization
of a neuromorphic brain prosthesis to replace a damaged neuronal
cluster in a multi-compartment neuronal network of dissociated
cortical neurons [87]. The neuromorphic computational model was
an implementation of a Spiking Neural Network (SNN), based on
Izhikevich model neurons [88].
Neuromorphic devices have been so far exploited for replacing
purposes. Nonetheless, the versatility at the core of their concept
promises theoretically unlimited implementations, including advanced
architecture and performance of bridging neuroprostheses.
Bridging neuroprostheses – In 2006 the group of Fetz [89] showed
that cortical reorganization can be induced by activity-dependent
plasticity achieved by implementing a causal relationship between
presynaptic and postsynaptic activities. Some years later, the group
led by Nudo [51] applied these ﬁndings to the treatment of stroke and
demonstrated the very ﬁrst example of a neural bridge aimed at
promoting functional re-connection between two cortical areas (i.e. the
premotor cortex and the somatosensory cortex) in a rat model of
Traumatic Brain Injury (TBI). The artiﬁcial bridge was based on an
activity dependent stimulation protocol (phase-locked reactive stimu-
lation, cf §4.1 - Neuromodulation) implemented through a custom,
wireless chip interconnecting the two far away cortical areas via closed-
loop interaction (cf Fig. 2).
3.4. Overview
From what has been described so far, it clearly shows that the
engineering strategies oﬀer a higher degree of functional control as
compared to biological approaches, because the human designer
programs the core operation of these devices, thereby instructing them
on how to behave. Yet, the limited ﬂexibility and the technological
constraints of most of these devices is a non-negligible cost. Indeed,
modern BMIs commonly enforce predeﬁned policies or they simply
provide for a unidirectional stereotyped replacement of the compro-
mised or lost brain function resulting somewhat stiﬀ in their operation.
Table 2 provides a key-points overview of advantages and limitations of
the described engineering approaches both in the experimental and
clinical settings.
At last, it needs to be stresses that the structural plasticity
phenomena that intrinsically characterize biological neurons can only
be simulated computationally in an artiﬁcial device whereas the
physical structure of its electronic components will remain unchanged.
This picture envisages the synergetic exploitation of the intrinsic
plasticity of biological neurons and of the high degree of control
oﬀered by engineering tools in order to achieve the necessary balance
between ﬂexibility and stability.
4. At the core of intelligent biohybrid systems: the history of
artiﬁcial intelligence and its implementation in neurobiology
& neuroengineering
The foundation of Artiﬁcial intelligence (AI) as an academic
discipline was laid by The Dartmouth Conference in 1956 (‘the birth
of AI’ [90]), where visionary scientists converged their world-changing
ideas with the commitment to build humane machines. In the wake of
this legacy, the treatment of neurological disorders has been revolu-
tionized by novel concepts based on the active implementation of AI to
neurobiology means. This cross-disciplinary approach based on con-
verging sciences has led to the unprecedented design of intelligent
biohybrid neurotechnologies, i.e. systems of biohybrid architecture
whose performance is enhanced by the additional implementation of
the theoretical principles of AI. These devices are based on a reciprocal
interaction between the biological and the artiﬁcial element(s) ulti-
mately aiming at establishing a functional partnership between them.
The artiﬁcial element is designed to provide an output (e.g.,
electrical stimulation, movement of a robotic arm) in response to an
input signal generated by the brain. As opposed to open-loop devices
providing a ﬁxed output independent of the ongoing brain activity
(Fig. 2a) and to closed-loop devices operating according to built-in
instructions (Fig. 2b), intelligent biohybrid systems operate in closed-
loop but they adapt their output to the input signal(s) received from the
brain area they are connected to (Fig. 3). The intelligent algorithms
implemented in these systems are capable of real-time adjustment,
since they are built upon an input/output (I/O) function that is set to
self-evolve and take autonomous decisions as to which intervention
policy is best at each point in time. Thus, intelligent biohybrid
neurotechnologies may reach high levels of sophistication up to
exhibiting autonomous goal-directed behavior.
In the next sections, we explain the concepts at the core of
intelligent operation and we present practical examples of these new
generation approaches, with particular emphasis on (1) intelligent
neuromodulation and (2) intelligent neuroprostheses, i.e., (i) replace-
ment and bridging based on neuromorphic performance, such as
memristor-based devices and organic electronic biomimetic neurons
and (ii) innovative BMIs.
4.1. Intelligent neuromodulation
Whether applied through the skull (tES) of directly into deep brain
structure (DBS), electrical modulation of brain activity may beneﬁt of
intelligent control algorithms to operate real-time adjustments of the
stimulation policy based on the detected ongoing brain signals.
In order to achieve the outstanding goal of prediction and preven-
tion of pathological brain discharges, more advanced designs have
leveraged statistical machine learning techniques. These strategies are
based on providing the algorithm with a goal as the sole parameter,
while letting it learn the best intervention policy through the presenta-
tion of learning problems. This paradigm is referred to as reinforce-
ment learning [91] and is distinguished from the supervised learning
technique used in responsive DBS algorithms in that it is not based on
examples provided by a knowledgeable external supervisor; rather it is
based on mapping (and linking) situations and actions in order to
maximize a numerical reward or a reinforcement signal. Algorithms
based on this paradigm do not receive any instruction on how to
behave (e.g., which stimulation to choose according to the detected
brain signal); they are programmed to discover which intervention
policy yields the highest reward by trial-and-error. Thus, reinforcement
learning is not deﬁned by characterizing learning methods, but by
characterizing a learning problem, where trial-and-error and delayed
reward are the two most salient features. The goal-directed behavior of
these intelligent agents relies on their capability of sensing the state of
the surrounding environment and of capturing its most relevant
aspects so to take consequent actions in relation to how the environ-
ment must be changed in order to maximize the reward. Sensation
(signal detection), action (stimulation) and goal (halting pathological
brain activity) are the three fundamental prerequisites for these
advanced neuromodulation algorithms, which are referred to as
adaptive ( Fig. 4), since they are capable of self-evolving and
autonomous decisional power ([2]). Reinforcement learning techni-
ques have been successfully implemented to build adaptive stimulation
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algorithms for seizure control using computer simulations and in vitro
models of epileptiform activity [92–94]. Based on a set of choices
derived from previously established periodic pacing policies [95,96],
the proposed adaptive design exhibited self-evolving behavior and
autonomous decisional power as to whether stimulation was required
at each point in time and to which stimulation policy to enforce. The
novel adaptive stimulation algorithm exhibited similar suppression
rate of seizure-like events when compared to the most eﬀective periodic
pacing policy (i.e., 1 Hz, cf [96]), while requiring the delivery of a
smaller number of electrical pulses, thereby beneﬁtting the brain tissue
of less electrical stress. Moreover, this work deﬁnitely clariﬁed the
importance of the stimulation pattern in addition to the target site (cf
[12]) by demonstrating that the eﬃcacy of seizure control was smaller
when applying periodic pacing at the average pulse frequency delivered
by the adaptive algorithm. In the broader perspective of imprinting
functional features to in vitro generated graft nervous tissue, this
aspect is highly relevant, since it further corroborates the vision that a
close dialogue between brain and machine is a crucial prerequisite to
obtain cutting-edge biohybrid transplants for functional brain repair.
As previously emphasized, improved therapeutic DBS treatments
may rely on the prediction of the ensuing undesirable brain activity
pattern, such as a seizure, in order to prevent, rather than halt, its
occurrence. Predictive algorithms may also be useful when it is
required that the response of the stimulated brain area be known in
advance so to operate a case-by-case choice of the best stimulation
policy in order to rectify pathological brain activity in real-time.
Needless to say, this is not a trivial achievement, as most predictive
algorithms are theoretically based on exact neurophysiology knowl-
edge, including the underlying dynamics and transition states (i.e.,
from normal to pathological activity) of the probed neuronal network
(so-called ‘ﬁrst principles’ approach). More recently, Keith Bush and
colleagues [97] have proposed an evidence-based mathematical mod-
eling approach, which is capable of capturing robust, informative
features of the state of neuronal networks. The described model is
built upon abstract rules, i.e. on the evidence acquired from observa-
tion independent of detailed neurophysiology knowledge. This ap-
proach is very intriguing, since it oﬀers the possibility of predicting the
outcome of neuromodulation and screening a variety of interventions
while bypassing the need of detailed knowledge of the probed neuronal
network dynamics as required by ﬁrst principles approaches. The
proposed evidence-based model may prove useful both as a simulator
and as a predictor, so to aid in the initial choice of stimulation
parameters based on simulation results as well as in the real-time ﬁne
tuning of adaptive stimulation algorithms based on real-time predic-
tion of the neuronal network response to electrical stimulation.
4.2. Intelligent neuroprostheses – replacement and bridging
Electronic memory transistors (memristors) are fundamental elec-
tronic circuit elements characterized by a dynamic relationship be-
tween current and voltage, whose most relevant feature is the capability
of retaining memory of past voltages or currents that have passed
through them. Memristors were formally introduced in 1971 by Leon
O. Chua [98]. In his seminal paper, Chua provided the ﬁrst mathema-
tical description of what he proposed to be the (theoretical) fourth
fundamental circuit element (along with capacitor, inductor and
resistor), which he named ‘memristor’ as a short from the term
‘memory resistor’. The existence of memristors has remained a
theoretical assumption until recently, when the groundbreaking work
by Dmitri B. Strukov and colleagues [99] demonstrated the natural
arising of memristive elements and their role in hysteretic phenomena
that are commonly observed in electronic devices as well as in
biological neurons (i.e., whenever a current-voltage relationship is in
play). Most relevant was the demonstration that a memristor can retain
the value of its most recent resistance even when the electric power
supply is turned oﬀ and remember it until it is next turned on. SinceTa
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this pioneering demonstration, memristors have been catching much
attention within the Computer and Electronic Engineering ﬁeld and,
more recently, within the neurotechnology ﬁeld and the brain repair
scientiﬁc community. Indeed, the performance of these electronic
elements resembles (rather than simulate) that of biological neurons,
since it combines the functions of memory and logic that are intrinsic
to synaptic plasticity and neurotransmission [98]. A further step
towards the generation of intelligent ‘self-evolving’ neuromorphic
devices has been recently made by Kuk-Hwan Kim and colleagues
[100]. The group has been able to create an artiﬁcial hybrid circuit
capable of mimicking the fundamental features of brain function by
stacking the ﬁrst functioning memristor array on a conventional
complementary metal-oxide semiconductor (CMOS) circuit. This out-
standing achievement is a critical progression in the development of
intelligent machines and opens the possibility of exploiting their
functional similarity to the brain as a repair strategy. Recent work
within the EU-funded project RAMP – Real neurons-nanoelectronics
Architecture with Memristive Plasticity – has indeed leveraged the
plasticity phenomena that can be easily induced in biological neurons
to imprint memories in memristors so to artiﬁcially mimic brain
function [101,102]. This design appears to be paradoxical, since the
electronic elements should interact with biological neurons to guide
their plasticity rather than acquiring it from them, whereas in this
paradigm ‘real’ neurons are exploited to improve the ﬂexibility and
thus the long-term (evolutionary) performance of the artiﬁcial device.
Nonetheless, memristors provide an intriguing perspective for the
design of biohybrid brain repair strategies by virtue of the high degree
of ﬂexibility that is inherent to their operating mode, which outclasses
the stereotyped behavior of most modern engineered controllers while
in turn oﬀering a more controllable behavior than real neurons.
However, it needs to be stressed that the electrical activity of the
surrounding (possibly) dysfunctional brain as well as the growth of the
anatomical component that would reconstitute the lost brain matter
cannot be modulated by memristors, which instead would integrate
themselves into a (most likely) pathological environment. Thus,
memristors might not suﬃce by themselves to heal a brain dysfunction
or might even end-up contributing to the worsening of it, unless
adequately designed.
Recent advances in biomimetic materials and organic electronics
have led to the unprecedented realization of organic electronic biomi-
metic neurons [103]. These artiﬁcial neuronal elements are distin-
guished from Artiﬁcial Neuronal Networks (ANN) by virtue of their
organic components along with highly sensitive chemical sensors and
ionic pumps that allow delivering neurotransmitters and generating
ionic currents in response to the chemical and electrical inputs received
from the brain tissue they are connected to. Thus, although artiﬁcial in
their manufacture, these ‘neuronal replicas’ actually behave like their
biological counterpart. A biohybrid solution based on organic artiﬁcial
neurons is highly intriguing and opens the visionary possibility of
reconstructing an artiﬁcial brain that is capable of fully resembling the
behavior of its biological counterpart. Nonetheless, as already stressed
for memristive devices, it remains to be established how these artiﬁcial
organic neurons can be guided to appropriately integrate themselves
within the damaged host nervous tissue and induce a functional healing
process that would not evolve towards pathological behavior. The
possibility of programming electronic neurons so to modulate their
output activity according to the desired functional features might
represent a fundamental leap in brain repair research, possibly eliminat-
ing the complex bench work required to generate biological neuronal
grafts with speciﬁc structural and functional features.
4.3. Intelligent neuroprostheses – innovative BMIs
In the BMI ﬁeld some examples of intelligent behavior can be found
in the routine regulating the operation of the decoding algorithm. In
general, given the variability and also the degradation of the quality
and quantity of the recorded brain signals, BMI performance tends to
decrease over time and also within a single BMI-training session. This
phenomenon could be tackled by continuous re-calibrations of the
decoder but this approach would detriment the structural plasticity of
the brain associated to the BMI task. To overcome these issues, the
group of Jose M. Carmena recently implemented adaptive behavior in
a BMI decoder design, which they deﬁne closed-loop decoder adapta-
tion (CLDA) [104]. The group demonstrated that this approach could
improve the initial BMI performance and compensate for changes in
neuronal recordings [104]. CLDA could be implemented using various
algorithms [105–107] and its purpose was to update the parameters of
the decoder according to past recorded data. CLDA was therefore
performed at the beginning of each session and within each session,
every time a signiﬁcant drop in BMI performance was observed. This
paradigm was used until the subject was able to successfully fulﬁll the
BMI task again.
4.4. Overview
Although promising, the neuroengineering approaches are still far
from being used in clinical applications. For example, in the case of BMI,
Bouton showed that the tetraplegic young man successfully learned to
use the neuroprosthesis and was able to play a toy electronic guitar in a
videogame, which requires coordination of fast, ﬁne ﬁnger movements.
However, the BMI was a bulky device and its set-up and operation
required the presence of the (skilled) research team. These major
constraints make the use of current BMIs in the daily life (and thus
their routine clinical application) impractical. However, the rapid
technological progress let us foresee the diﬀusion of such systems in
the next decades. For instance, wireless communication would free BMI
users from cables and plug outlets, while allowing physicians to remotely
monitor the functional state of the machine. Nanotechnologies applied to
miniaturized computers might help put aside bulky BMIs and open a
new era of ‘portable’ neuroprosthetic devices.
5. What are we still missing?
Many of the described approaches are groundbreaking achieve-
ments that have made possible what used to be a dream until a few
performance
evaluation
trial n
trial +1n
trial +2n
Fig. 4. Intelligent biohybrid systems implement adaptive control algorithms. An
intelligent neuromodulator is depicted. The device receives feedback (thick arrow-lines)
from the brain (grey trace) and from the performance evaluator, a programmed routine
that compares the actual output (modulated brain pattern, black traces) with the desired
output at each trial. Good and bad performances are scored according to a reward
function built in the evaluator program. Performance evaluation implies a learning
process so that the algorithm modiﬁes its intervention policy according to its past
experience, aiming at maximizing a reward. Ultimately the intelligent neuromodulator
adapts its behavior and becomes autonomous: it chooses the most appropriate action at
each point in time, independent of human intervention.
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decades ago. Cell transplantation and ‘mini-brains’, intelligent neuro-
modulation algorithms that learn from experience and outclass the
human knowledgeable operator, BMIs allowing to read emails, play
videogames or even perform complex coordinated ﬁne movements will
surely lead the era of novel intelligent biohybrid systems for functional
brain repair. Nonetheless, we cannot stress enough that each of these
strategies alone, at their current state of the art, will likely fail the
challenge of routine clinical application due to their inherent draw-
backs. The depicted points evidence the need of reaching beyond the
current state of the art and design unconventional brain repair
strategies that would make the most out of the good of biology and
engineering means. Speciﬁcally:
(1) Implantable artiﬁcial devices are prone to trigger foreign body
reaction [108] which is detrimental both for the patient and for the
implanted device. For example, the stability of electrical signals
recorded with intracortical electrodes is subject to degradation
over time due to the formation of reactive tissue against the
electrodes [109]. Bouton and colleagues [79] indeed reported that
the number of recorded signals from individual neurons dimin-
ished from 50 to 33 in as little as 15 months. As closed-loop
neurotechnologies are by nature based on the detection of brain
electrical signals in order to operate, the degradation of their
quality and quantity is an unacceptable shortcoming and research
is already exploring new strategies to overcome this major limita-
tion [104]. Along with the constant search of new biocompatible
materials, signiﬁcant advancements have been recently achieved in
the ﬁeld of implantable organic electronics by including a micro-
ﬂuidic component [110]. These novel ‘all-in-one’ implantable
technologies allow delivering drugs both as therapeutic agents
and as suppressors of the immune reaction directly from the
implanted device, promising to cross out the substantial drawback
carried by the foreign body reaction in the near future.
(2) The plasticity phenomena that are intrinsic to biological neurons
are a fundamental prerequisite to achieve the functional reestab-
lishment of the injured brain. However, as neuronal plasticity
intrinsically implies the risk of losing control over a biological
neuronal graft, tools from control theory are crucial to guarantee
the functional stability of the grafted nervous tissue and of the
brain hosting it. On the other hand, a too stiﬀ control algorithm
will inevitably compromise ﬂexibility and thus decrease the chance
of integration of the graft into the host nervous tissue.
Undoubtedly, to overcome these limitations it is required that a
highly ﬂexible synergetic interaction between artiﬁcial and biolo-
gical components be established. In this scenario, artiﬁcial intelli-
gence may represent the solution to orchestrate the seamless
integration of the biohybrid graft within the damaged brain while
providing a controlled environment. As described above, some
solutions to these primary issues have been recently proposed. For
example, the intrinsic plasticity of biological neurons is being
exploited with promising outcome to generate advanced highly-
performing memristors [101,102], while organic electronic biomi-
metic neurons have been recently proposed as a highly realistic
artiﬁcial replacement of their biological counterpart [103].
(3) It would be highly desirable to be able to rely on brain repair
strategies that are not disease-speciﬁc in their design, whereas
current biohybrid neurotechnologies are mainly conceived to
target a speciﬁc CNS dysfunction. It may be argued that detailed
knowledge of brain pathways is a prerequisite to restore their
function and that the repair strategy cannot overlook essential
anatomical and (patho)physiological information. Moreover, such
a revolutionary achievement would require identiﬁcation of the
functional ‘building-blocks’ of neuronal communication and
knowledge of the relation between structure and function of
neuronal networks. This missing knowledge is crucial to under-
stand how diﬀerent combinations of functionally distinct building-
blocks may be exploited to achieve the desired functional features
of neuronal grafts and to predict their inﬂuence on the activity of
the extended neuronal network they would be embedded in (the
brain). In this context, a ‘reverse engineering’ approach might be a
valuable asset to bypass the need of detailed biophysical models
based on ﬁrst principles and possibly the need of extensive
anatomical and functional characterization of neuronal pathways.
Indeed, as recently demonstrated [97], computational approaches
exploiting an evidence-based strategy make it possible to faithfully
reproduce the responses of brain tissue to electrical inputs and
thus to also predict how a brain area would react to a variety of
electrical input patterns, even without prior observation of the
neuronal network dynamics. It is reasonable to anticipate that in
the near future it will be possible to reverse the operating mode of
prediction and simulation algorithms so to establish which missing
input signal should be replaced in a dysfunctional brain in order to
recover the desired electrical activity. In turn, this would allow
imprinting the desired functional features to engineered nervous
tissue to be used as graft and ultimately anticipating the outcome
of its interaction with the host brain.
6. Concluding remarks
We have stepped through the historical developments of brain
repair strategies from the origin of groundbreaking discoveries and the
seeds of revolutionary visions to the actual realization of previously
fantasized intelligent biohybrid neurotechnologies. We provide a visual
overview in Fig. 5 to help explore possible new roadmaps to beat the
challenge of defeating CNS dysfunctions. There are still many open
questions to be answered and as many obstacles to be overcome.
However, in the era of exponential progression in medicine and
technology, we envisage the future possibility of inducing a self-repair
process in a damaged brain thanks to the availability of versatile, highly
eﬃcient, cost-eﬀective intelligent biohybrid neurotechnologies that will
oﬀer personalized interventions to “help the brain help itself” [111].
7. Executive summary
• Neurotechnologies are artiﬁcial means to understand and/or mod-
ulate brain function.
• Intelligent biohybrid neurotechnologies are neurotechnologies
based on the joint exploitation of biological and artiﬁcial compo-
nents, whose interaction is mediated by intelligent control algo-
rithms.
• The development of intelligent biohybrid neurotechnologies for
functional brain repair will lead to the global engagement of
research and industry establishing an unprecedented explosion of
cross-disciplinary translational biomedical research.
• Achievement of a smooth self-repair process in the damaged brain
will drop the global burden and the societal impact of neurological
diseases, while abating the cost of (often ineﬃcient and too
aggressive) canonical treatments.
• Brain self-repair strategies based on a non disease-speciﬁc design
will oﬀer treatments that are intrinsically tailored to the patient's
need.
• The ‘self-repair’ therapeutic approach will simplify the approval
procedures of regulatory agencies.
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